Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

A real-world study on first-line early switch to kpd regimen in the treatment of multiple myeloma patients with suboptimal induction efficacy or intolerance

View Full Paper
Ask AI
Bookmark
Share

Authors

XJXu JiYBYanliang BaiWQWen Qin

Discussion

Loading...

Member takes

Overview

Real-world study shows high response rates in multiple myeloma patients switching to KPD therapy, indicating improved outcomes and manageable adverse events.

Key Points

  • To evaluate the efficacy and safety of the KPD regimen in multiple myeloma patients with suboptimal induction responses.
  • Multicenter study involving patients from 12 medical centers in Henan Province
  • Participants switched to KPD after not achieving VGPR or experiencing intolerable adverse events from initial therapy
  • Response assessed after 2-4 cycles of KPD treatment, focusing on overall response rate and safety outcomes
  • 91.23% overall response rate observed after KPD therapy
  • 56.14% of patients achieved complete response or better
  • Safety issues included neutropenia (8.7%), anemia (36.84%), and arrhythmia (19.3%)

Cite This Study

Ji et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e280https://doi.org/10.1182/blood-2025-7548
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world efficacy and safety of the carfilzomib–pomalidomide–dexamethasone regimen in patients with relapsed/refractory multiple myeloma: A multicenter retrospective study2026
  2. 2An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT study2024 · 17 citations
  3. 3Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) induction prior to autologous haematopoietic stem cell transplant/transplantation in newly diagnosed multiple myeloma2026
  4. 4Aponermin combined with carfilzomid-pomalidomide-dexamethasone (KPd) in patients with relapsed or refractory multiple myeloma: A prospective, open-label, multicenter study2025
  5. 5Comparative Effectiveness of Pomalidomide-Based Regimens in Relapsed/Refractory Multiple Myeloma: A Multicenter Real-World Analysis in China2026